Effect of Immunotherapy with Allogeneic Lymphokine-activated Killer Cells and Recombinant Interleukin 2 on Established Pulmonary and Hepatic Metastases in Mice

Keyphrases

• Recombinant interleukin-2 100%
• Lymphokine-activated Killer Cells 100%
• Natural Killer Cells 100%
• Pulmonary Metastasis 100%
• Allogeneic 100%
• Hepatic Metastasis 100%
• C57BL 25%
• Syngeneic 25%
• Micrometastasis 18%
• Tumor 12%
• Adoptive Transfer 12%
• Therapeutic Benefits 6%
• Immunogenic 6%
• Lysis 6%
• Tumor Cells 6%
• Increased Dose 6%
• Antitumor Efficacy 6%
• Tumor Targeting 6%
• 51Cr Release Assay 6%
• 2-dose 6%
• Systemic Administration 6%
• Donor Cells 6%
• Therapeutic Approaches 6%
• Murine Tumors 6%
• Therapeutic Effect 6%
• Antitumor Effect 6%
• Major Histocompatibility Complex 6%
• Histocompatibility Antigens 6%
• Copyright 6%
• Intraportal 6%
• Lytic Activity 6%
• Non-immunogenic 6%
• H-2B 6%
• Sarcoma Metastasis 6%
• Dose Titration 6%
• Extent of Reduction 6%
• Pulmonary Sarcoma 6%
• Titration Experiment 6%

Immunology and Microbiology

• Drug Dose Titration 6%